ReGen Biologics, Inc. Closes Bridge Financing
Published: Oct 06, 2009
HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBO) announced today that it has entered into a bridge financing agreement for up to $3 million aggregate principal amount of secured convertible notes (“Notes”) and closed on the first tranche of the agreement with one of its principal investors. In the first closing under the bridge financing, the Company received $250,000 in immediately available funds and initial commitments for $1.5 million to be provided to the Company in increments to be established with the investors.